biostudies-literatureMenzen MNovo Nordisk205-215https://www.ebi.ac.uk/biostudies/studies/S-EPMC10101737biostudies-literatureUnknown131(4)<h4>Context</h4>Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established in the phase 3 SUSTAIN trials, which included patients across the continuum of type 2 diabetes care. It is useful to complement these findings with real-world evidence.<h4>Objective</h4>SURE Germany evaluated once-weekly semaglutide in a real-world type 2 diabetes patient population.<h4>Design/setting</h4>The prospective observational study was conducted at 93 clinical practices in adults with+≥ 1 documented glycated haemoglobin value ≤12 weeks before initiation of semaglutide.<h4>Intervention</h4>Once-weekly semaglutide was prescribed at the physicians' discretion.<h4>Main outcomes</h4>The primary endpoint was change in glycated haemoglobin from baseline to end-of-study (~30 weeks). SecondarExperimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes AssociationReal-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.PMC10101737NAMenzen MBerentzen TLSimon JPieperhoff SJacob SCatarig AMfalseReal-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.<h4>Context</h4>Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established in the phase 3 SUSTAIN trials, which included patients across the continuum of type 2 diabetes care. It is useful to complement these findings with real-world evidence.<h4>Objective</h4>SURE Germany evaluated once-weekly semaglutide in a real-world type 2 diabetes patient population.<h4>Design/setting</h4>The prospective observational study was conducted at 93 clinical practices in adults with+≥ 1 documented glycated haemoglobin value ≤12 weeks before initiation of semaglutide.<h4>Intervention</h4>Once-weekly semaglutide was prescribed at the physicians' discretion.<h4>Main outcomes</h4>The primary endpoint was change in glycated haemoglobin from baseline to end-of-study (~30 weeks). Secondar2023-01-01T00:00:00Z2023 Apr2026-07-14T19:05:53.183Z2025-04-07T03:15:27.897ZS-EPMC101017373659945910.1055/a-2007-2061